| Literature DB >> 35055408 |
Pim Cuijpers1, Marketa Ciharova1, Soledad Quero2,3, Clara Miguel1, Ellen Driessen4, Mathias Harrer5, Marianna Purgato6,7, David Ebert8, Eirini Karyotaki1.
Abstract
While randomized trials typically lack sufficient statistical power to identify predictors and moderators of outcome, "individual participant data" (IPD) meta-analyses, which combine primary data of multiple randomized trials, can increase the statistical power to identify predictors and moderators of outcome. We conducted a systematic review of IPD meta-analyses on psychological treatments of depression to provide an overview of predictors and moderators identified. We included 10 (eight pairwise and two network) IPD meta-analyses. Six meta-analyses showed that higher baseline depression severity was associated with better outcomes, and two found that older age was associated with better outcomes. Because power was high in most IPD meta-analyses, non-significant findings are also of interest because they indicate that these variables are probably not relevant as predictors and moderators. We did not find in any IPD meta-analysis that gender, education level, or relationship status were significant predictors or moderators. This review shows that IPD meta-analyses on psychological treatments can identify predictors and moderators of treatment effects and thereby contribute considerably to the development of personalized treatments of depression.Entities:
Keywords: depression; individual participant data meta-analysis; moderators; predictors; psychotherapy
Year: 2022 PMID: 35055408 PMCID: PMC8781368 DOI: 10.3390/jpm12010093
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Figure 1Flowchart for the inclusion of studies.
Selected characteristics of IPD meta-analyses and IPD network meta-analyses on psychotherapies for adult depression.
| AMSTAR-2 a) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Intervention | Comparison | Type b) | Nst | Npart | Proportion | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Tot Y/PY |
| Bower et al., 2013 [ | Low intens. CBT | Usual care | ma | 16 | 2470 | 55.2 (16/29) | Y | N | Y | N | N | Y | N | PY | N | N | Y | Y | Y | N | Y | Y | 9 |
| Weitz et al., 2015 [ | CBT | ADM | ma | 16 | 1700 | 66.7 (16/24) | Y | Y | Y | PY | Y | N | N | Y | Y | N | Y | Y | Y | Y | N | Y | 12 |
| Reins et al., 2020 [ | Indicated prevention | Usual care or WL | ma | 7 | 2186 | 87.5 (7/8) | Y | N | Y | PY | N | N | N | Y | Y | N | N | Y | Y | N | N | Y | 8 |
| Furukawa et al., 2017 [ | CBT | Pill placebo | ma | 5 | 509 | 100 (5/5) | Y | Y | Y | PY | N | N | N | PY | Y | Y | Y | Y | Y | Y | Y | Y | 13 |
| Karyotaki et al., 2018 [ | Guided iCBT | Any control | ma | 24 | 4889 | 88.9 (24/27) | Y | N | Y | PY | Y | N | N | Y | Y | N | Y | Y | Y | Y | Y | Y | 12 |
| Karyotaki et al., 2017 [ | Unguided iCBT | Any control | ma | 13 | 3876 | 81.3 (13/16) | Y | N | Y | PY | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | N | 12 |
| Kuyken et al., 2016 [ | MBCT | Any control or active treatment | ma | 10 | 1258 | 90.0 (9/10) | Y | Y | Y | PY | N | Y | N | Y | Y | N | Y | Y | Y | Y | Y | Y | 13 |
| Driessen et al., 2020 [ | Dynamic+ADM | ADM | ma | 7 | 482 | 100 (7/7) | Y | N | Y | PY | N | N | N | PY | Y | N | Y | Y | Y | Y | Y | Y | 11 |
| Furukawa et al., 2018 [ | CBASP vs. ADM | vs. COMB | nma | 3 | 1036 | 100 (3/3) | Y | Y | Y | PY | N | N | N | Y | PY | N | N | Y | Y | N | N | Y | 9 |
| Karyotaki et al., 2021 [ | Guided iCBT vs. Unguided iCBT | vs. any control | nma | 39 | 8107 | 92.9 (39/42) | Y | N | Y | PY | N | N | N | PY | PY | N | Y | Y | Y | Y | Y | Y | 11 |
a) The AMSTAR-2 items refer to 1. the use of participants, intervention, comparator, outcome (PICO) in formulating the research question, 2. whether the methods were established before the review was conducted, 3. an explanation for the selection of the study design to be included, 4. the comprehensiveness of the search strategy, 5. study selection by at least two reviewers, 6. data extraction by at least two reviewers, 7. providing a list of excluded studies with reasons, 8. a detailed description of included studies, 9. assessment of risk of bias in included studies, 10. reporting sources of funding for the included studies, 11. appropriate methods for pooling results of individual studies, 12. assessment of the impact of risk of bias on the outcomes, 13. a discussion of the impact of risk of bias on results, 14. an explanation and discussion of heterogeneity, 15. assessment of publication bias, 16. reporting potential conflict of interest and funding for the review. b) Type of IPD meta-analysis (ma = pairwise IPD meta-analysis; nma = IPD network meta-analysis). Abbreviations: ADM: antidepressant medication; CBASP: Cognitive Behavioral Analysis System of Psychotherapy; CBT: cognitive behavioral therapy; COMB: combined treatment; Dynamic: psychodynamic psychotherapy; iCBT: internet-based CBT; Low intens. CBT: low-intensity CBT; MBCT: mindfulness-based CBT; Npart: number of participants; Nst: number of studies; Tot Y/PY: total number of “Yes” on all AMSTAR-2 domains; vs: versus; WL: waiting list; N: No; PY: Probably yes.
Figure 2AMSTAR-2 ratings of included studies. Abbreviations: PICO: Participants, Intervention, Comparator, Outcome; RoB: risk of bias.
Effect sizes and predictors identified in IPD meta-analyses of psychotherapies for adult depression.
| Study | Contrast a) | Effect Size | Significant Predictors/Moderators b) | Non-significant Predictors/Moderators c) |
|---|---|---|---|---|
|
| ||||
| Bower et al., 2013 [ | Low-intensity CBT vs. CTR | CBT > CTR: SMD = −0.42 | SPE: Baseline severity | - |
| Weitz et al., 2015 [ | CBT vs. ADM | ADM > CBT (on HAM-D: | - | SPE/NSP/MOD: Gender MOD: Baseline severity |
| Furukawa et al., 2017 [ | CBT vs. pill placebo | CBT > placebo: SMD: −0.22 | - | SPE: Baseline severity |
| Karyotaki et al., 2018 [ | Guided iCBT vs. CTR | Guided iCBT > CTR; OR = 2.49 response; OR = 2.41 remission | SPE: Older age; native-born; baseline severity | SPE: Sex; relationship; education; medication use; anxiety; previous episodes; alcohol problems |
| Karyotaki et al., 2017 [ | Unguided iCBT vs. CTR | Unguided iCBT > control; g = 0.27 | SPE: None | SPE: Age, sex, education, relation-ship status anxiety, baseline severity |
| Kuyken et al., 2016 [ | MBCT for relapse vs. CTR | MBCT > CTR: HR of relapse = 0.69 (95% CI: 0.58; 0.82) | SPE: Baseline severity | SPE: Age, sex, education, relationship status |
| Driessen et al., 2020 [ | Dynamic vs. combined treatment | Combined > dynamic therapy; d = 0.26 | - | - |
| Reins et al., 2020 [ | Internet interventions for subthreshold depression | Internet interventions > control; d = 0.39 | SPE: Higher baseline severity; Older age | SPE: Gender; relationship; employment; previous therapy; medication use; anxiety; medical condition; education |
|
|
| |||
| Furukawa et al., 2018 [ |
CBASP for persistent depression |
COMB > CBASP: 2.9 (1.3; 4.6) HAMD points COMB > ADM: 2.9 (1.6; 4.3) HAMD points CBASP = ADM: 0.1 (−1.6; 1.7) HAMD points |
Examined moderators/predictors: Baseline depression, anxiety, prior medication, childhood neglect, and several interactions Outcomes: Baseline depression, anxiety, prior pharmacotherapy, age, and depression subtypes moderated their relative efficacy. URL: | |
| Karyotaki et al., 2021 [ |
Guided and unguided iCBT |
g-iCBT > u-iCBT: −0.8 (−1.4; −0.2) PHQ-9 points g-iCBT > TAU: −1.7 (−2.3; −1.1) PHQ-9 points g-iCBT > WL: −3.3 (−3.9; −2.6) PHQ-9 points u-iCBT > TAU: −0.9 (−1.5; −0.3) PHQ-9 points u-iCBT > WL: −2.5 (−3.2; −1.8) PHQ-9 points |
Examined moderators/predictors: Baseline severity, age, sex, educational level, relationship status, employment status, treatment adherence. Outcomes: Baseline severity was the most important moderator. In mild depression differences between unguided and guided iCBT were small; in more severe depression guided iCBT is more effective. URL: | |
a) Extensive definitions of the different types of therapies can be found in Cuijpers et al., 2020. b) Predictors defined as characteristics that indicate whether a patient benefits from a treatment or not. Specific predictors (SPEs) indicate whether a specific characteristic predicts outcome of therapy compared to a no-treatment control, while non-specific predictors (NPEs) indicate variables that are related to improvement, regardless of comparison or control group (within-group improvement). Moderators (MODs) are characteristics that indicate which patients benefit more from one treatment compared to another treatment. c) Because these studies are based on large sample sizes, non-significant variables are also important because they are probably not associated with the outcome. Abbreviations: ADM: antidepressant medication; CBASP: Cognitive Behavioral Analysis System of Psychotherapy; CBT: cognitive behavioral therapy; CTR: control group; HAM-D: Hamilton Rating scale for depression; HR: hazard ratio; iCBT: internet-based CBT; IPD: individual participant data; MBCT: mindfulness-based CBT; MOD: moderator; NSP: non-specific predictor; OR: odds ratio; PHQ-9: Patient Health Questionnaire-9 items; SMD: standardized mean difference; SPE: specific predictor; TAU: treatment as usual; u-iCBT: unguided iCBT; WL: waiting list.